Price
$2.01
Increased by +1.01%
Dollar Volume (20D)
43.61 K
ADR%
4.83
Earnings Report Date (estimate)
Oct 27, 23 (-0.85)
Market Cap.
33.51 M
Shares Float
12.80 M
Shares Outstanding
16.67 M
Beta
1.76
Price / Earnings
-0.61
BPR
0.47
20D Range
1.81 2.19
50D Range
1.81 3.18
200D Range
1.75 4.69
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 11, 23 0.11
Increased by +111.58%
0.87
Decreased by -87.36%
Apr 28, 23 -1.29
Decreased by -35.79%
-4.05
Increased by +68.15%
Mar 24, 23 -1.04
Decreased by -30.00%
-0.89
Decreased by -16.85%
Oct 28, 22 -0.80
Decreased by -33.33%
-0.95
Increased by +15.79%
Aug 12, 22 -0.95
Decreased by -171.43%
-0.60
Decreased by -58.33%
Apr 27, 22 -0.95
Decreased by -46.15%
-0.52
Decreased by -82.69%
Mar 25, 22 -0.80
Increased by +78.67%
-0.72
Decreased by -11.11%
Oct 26, 21 -0.60
Decreased by -20.00%
-0.65
Increased by +7.69%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jul 6, 23 12.00 M
Increased by +N/A%
-1.89 M
Increased by +82.75%
Decreased by -15.71%
Decreased by N/A%
Jun 30, 23 12.00 M
Increased by +N/A%
-1.89 M
Increased by +85.37%
Decreased by -15.71%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-19.11 M
Decreased by -48.19%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
-14.48 M
Decreased by -69.28%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
-10.93 M
Decreased by -101.32%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-12.89 M
Decreased by -295.32%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-12.90 M
Decreased by -225.75%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-8.55 M
Decreased by -64.98%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.